Gastrointestinal and Health-related Quality of Life in Kidney Transplant Patients Treated With Mycophenolate Mofetil

Maintenance Kidney Transplant Clinical Trial

Official title: A 12-week Multicenter, Randomized, Open Study to Evaluate the Effects of Enteric-coated Mycophenolate Sodium (EC-MPS) in Terms of Quality of Life in Patients With Gastrointestinal (GI) Symptoms Treated With MMF (Mycophenolate Mofetil) After Kidney Transplant.

Status Completed

Clinical Trial Summary

This study will assess the quality of life in renal transplant recipients who require a reduced dose of mycophenolate mofetil (MMF) because of gastrointestinal (GI) side effects and will also access the relationship between mycophenolic acid (MPA) dose in those patients receiving enteric-coated mycophenolate sodium formulation(EC-MPS).

Patients will be evaluated at baseline, 2 weeks after study medicine conversion and then again at 12 weeks post-conversion.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Maintenance Kidney Transplant

• NCT number: NCT00400647
• Study type: Interventional
• Source: Novartis
• Status: Completed
• Phase: Phase 4
• Start date: July 2006
• Completion date: September 2008